- Strategy
- Payers
- AI
- Cybersecurity
- Device Development
- Studies/Published Research
- Ethics
- Regulatory
- Digital Biomarkers
- Data Science
- Companion Diagnostics
- Clinical Care
- Digital Therapeutics
- Academic Research
- Virtual Reality
- RWE
- Digital Endpoints
- Medical Devices (Class II and Class III)
- Commercialization
- Clinical Trials
- Drug-Device Combinations
- SaMD
- Remote Patient Monitoring
- Patient Engagement
- Profiles/Q&A
Noze Receives Grant for Breathalyzer to Detect Infectious Diseases
The goal is to enable rapid screening and diagnostics of infectious diseases such as malaria and tuberculosis, which will be readily accessible to all population groups.
Canadian AI startup Noze, which has developed technology to digitize the sense of smell, announced a grant of $1 million from the Bill & Melinda Gates Foundation to build a breathalyzer to detect breath biomarkers (VOCs). The goal is to enable rapid screening and diagnostics of infectious diseases such as malaria and tuberculosis, which will be readily accessible to all population groups. Development of the diagnostic breathalyzer is targeted for completion by the end of 2023, which will be followed by a clinical validation phase.
During the COVID-19 pandemic, Noze’s technology was the first shown to have capabilities to track the airborne markers released by persons infected with the coronavirus and influenza. This advancement opened the door to solving other healthcare challenges by leveraging the digital sense of smell. Noze is also actively developing other health-related projects with additional partners, including the Montreal Heart Institute, with clinical trials underway that utilize the company’s digital odor perception platform.
Reference: Noze Receives $1 Million Grant from Major Global Foundation to Build the World’s First Breathalyzer to Detect Infectious Diseases.MONTREAL – March 14, 2023
